Vita Fontana
Family · Detroit, MINPI 1427664986
Payments from drug & device makers
Across 69 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$209
- GSK$141
- Amgen$135
- Johnson & Johnson$133
- Incyte Corporation$128
- Genentech USA, Inc.$115
- plus $872 from 24 others
What the payments were for
- Food & beverage$1,41482%
- Education$32018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $209 |
| GSK | 4 | $141 |
| Amgen | 6 | $135 |
| Johnson & Johnson | 3 | $133 |
| Incyte Corporation | 5 | $128 |
| Genentech USA, Inc. | 5 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $97 |
| Blueprint Medicines Corporation | 3 | $76 |
| AstraZeneca | 1 | $75 |
| Pfizer | 4 | $70 |
| Seagen Inc. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Sobi, Inc | 1 | $33 |
| Emmaus Medical, Inc. | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Invivyd Inc | 1 | $28 |
| Sanofi | 1 | $28 |
| Taiho Oncology, Inc. | 1 | $26 |
| Bayer | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Merck | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $24 |
| Geron Corporation | 1 | $23 |
| AbbVie | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $19 |
| Beigene USA, Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Morphosys, US Inc. | 1 | $15 |
How this compares
$1,734 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $42,964 |
| Letrozole | 31 | $2,365 |
| Anastrozole | 56 | $2,365 |
| Fentanyl | 14 | $1,706 |
| Acyclovir | 59 | $1,679 |
| Dexamethasone | 51 | $1,301 |
| Prochlorperazine Maleate | 85 | $1,138 |
| Ondansetron Hcl | 13 | $786 |
| Hydroxyurea | 19 | $652 |
| Pantoprazole Sodium | 35 | $622 |
| Ondansetron OdtOndansetron | 16 | $429 |
| Omeprazole | 18 | $418 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $381 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 18 | $354 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 28 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $42,96436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Detroit
- Elisheva EllenbergDetroit$150K
- Michelle ThomasDetroit$36K
- Danielle BlakeDetroit$34K
- Lauren JuddDetroit$15K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.